We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapeutic Thoracentesis for Patients With Congestive Heart Failure and Large Pleural Effusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00629538
Recruitment Status : Completed
First Posted : March 6, 2008
Last Update Posted : December 30, 2010
Sponsor:
Information provided by:
Taipei Medical University Hospital

Brief Summary:
Transudative pleural effusions are a common manifestation of patients with congestive heart failure. Severe dyspnea and respiratory failure may develop in those with large effusions, which in general show poor response to medical treatment. Therapeutic thoracenteses (TT) may be indicated in these patients and can produce marked relief of symptoms. However, the underlying effect of TT on gas exchange and respiratory mechanics in theses patients remains unclear. The researchers' hypothesis is that,TT may improve arterial oxygenation and respiratory mechanics in patients with congestive heart failure complicated by large pleural effusions.

Condition or disease Intervention/treatment
Congestive Heart Failure Transudative Pleural Effusion Procedure: Therapeutic thoracentesis

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Therapeutic Thoracentesis on Cardiopulmonary Function in Patients With Congestive Heart Failure Complicated With Large to Massive Pleural Effusion
Study Start Date : March 2007
Primary Completion Date : July 2009
Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources


Intervention Details:
    Procedure: Therapeutic thoracentesis
    Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.


Primary Outcome Measures :
  1. Vital signs, minute volume, expiratory tidal volume, dynamic compliance, arterial oxygen saturation and arterial blood gases, the volume of pleural fluid removed, and the changes in pleural liquid pressure and pleural space elastance [ Time Frame: 15 minutes after therapeutic thoracentesis ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • transudative pleural effusion established by the criteria of Light
  • the effusion occupying at least half of one hemithorax shown on chest radiography
  • symptoms of respiratory distress
  • diagnosis of congestive heart failure

Exclusion Criteria:

  • severe uncontrolled coagulopathy
  • unstable hemodynamics
  • diagnosis of liver cirrhosis, chronic obstructive pulmonary disease,asthma and/or any parenchymal lung disease, such as pneumonia, fibrosis or malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00629538


Locations
Taiwan
Taipei Medical University Hospital
Taipei, Taiwan, 110
Sponsors and Collaborators
Taipei Medical University Hospital
Investigators
Principal Investigator: Chi-Li Chung, MD, PhD Department of Internal Medicine, Taipei Medical University Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Chung, Chi-Li/Chest physician of Department of Internal Medicine, Taipei Medical University Hospital
ClinicalTrials.gov Identifier: NCT00629538     History of Changes
Other Study ID Numbers: TMUHIRB20070304
First Posted: March 6, 2008    Key Record Dates
Last Update Posted: December 30, 2010
Last Verified: December 2010

Keywords provided by Taipei Medical University Hospital:
congestive heart failure
thoracentesis
transudative pleural effusions

Additional relevant MeSH terms:
Heart Failure
Pleural Effusion
Hydrothorax
Heart Diseases
Cardiovascular Diseases
Pleural Diseases
Respiratory Tract Diseases